This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...
CRA Life Sciences experts Tim Wilsdon, Michele Pistollato, Antun Sablek, and Qinyi Wang contributed to a research article
Annabelle Fowler presents the CRA paper titled “An Analysis of Medicaid CPI Rebates and the Sustainability of U.S. Generic Markets.” Ashutosh Mishra presents...
Ryan Lawlor presents the session titled “Prioritising Alzheimer’s Disease in Europe: Next steps for Policy Action.” Tim Wilsdon moderates the panel discussion...
CRA and leading European payer experts hosted a 30-minute virtual webinar to explore how growing competitive dynamics are reshaping the rare diseases market...
Abhishek Kumar presents his poster titled “Top Trends Affecting the Vaccines Market and their Implications on Access Policy and Public Health...
